Krystal Biotech (KRYS) investor relations material

Financial performance and growth

• Generated over $730M in net revenue from VYJUVEK since launch, with 10 consecutive quarters of positive EPS and $955.9M in cash and investments as of 4Q 2025.

• Two U.S. CGMP manufacturing facilities totaling over 175,000 sq ft support scalable production.

VYJUVEK for dystrophic epidermolysis bullosa (DEB)

• First corrective therapy for DEB, a severe genetic skin disorder affecting ~9,000 globally, with high annual care costs and cancer risk.

• Demonstrated significant wound healing efficacy and strong safety in pivotal trials, with 68% wound closure at 3 months vs. 23% for placebo.

• Well tolerated with mostly mild or moderate adverse events and no treatment discontinuations or deaths.

• Approved in the U.S. for all ages and DEB subtypes, with label expansions increasing flexibility and home use.

• Global expansion underway, with launches in France, Germany, and Japan, and distribution agreements in 20+ countries.

Pipeline and platform

• Proprietary redosable HSV-1 vector platform enables non-invasive gene delivery to skin, lung, and eye, with FDA platform technology designation.

• Deep pipeline includes candidates for cystic fibrosis (KB407), alpha-1 antitrypsin deficiency (KB408), ocular DEB (KB803), neurotrophic keratitis (KB801), Hailey-Hailey disease (KB111), and oncology (KB707).